MONTREAL, QUEBEC -- (MARKET WIRE) -- May 09, 2007 -- Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, announced today the first quarter 2007 financial results and provided an update on its development program.
